Commentaries

 

IAPP-driven metabolic reprogramming induces regression of p53-deficient tumours in vivo. 
a. McCarthy N. Feed a cold, starve a tumour; Nature Reviews Cancer 15, 4–5 (2015). b. Link. Induction of Metabolic Reprogramming Suppresses p53-Null Tumor Growth; .
TAp63 is the master transcriptional regulator of lipid and glucose metabolism
a. Burgess DJ. Metabolism: TAp63 tips the energy balance? Nat Rev Cancer. 2012;12(11):736-7.
TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs
a. Mitchell L. Brothers in arms against cancer. Vol.331 no. 6024, 1551-1552. Science March 25 2011
http://www.sciencemag.org/content/331/6024/1551.full
b. Alderton G.K. Tumor suppression: The burning issue of p63. Nature Reviews Cancer 10, 814-815 (December 2010)
http://www.nature.com/nrc/journal/v10/n12/full/nrc2978.html
c. Valastyan, S. and Weinberg, R. Metastasis suppression: The role of Dice(r). Genome Biology 2010, 11:141
http://genomebiology.com/2010/11/11/141
d. Faculty of 1000 – rated 8 (Laura Attardi, Ph.D., Associate Professor, Stanford University)
DeltaNp63 transcriptionally regulates brachyury, a gene with diverse roles in limb development, tumorigenesis and metastasis
a. Sinha S. Breaking into the Brachury world: ΔNp63 joins in. Cell Cycle News and Views, 2489-2499, July 1 2010.
http://www.landesbioscience.com/journals/cc/article/12238/
TAp63 prevents premature aging by promoting adult stem cell maintenance
a.Beaudry, V.G. and Attardi L.D. SKP-ing TAp63: Stem Cell Depletion, Senescence and Premature Aging. Cell Stem Cell, 1-2, 2 July 2009
http://www.cell.com/cell-stem-cell/retrieve/pii/S193459090900294X
 
p63 and p73 are required for p53-dependent apoptosis in response to DNA damage
a.Urist M. and Prives C. p53 leans on its siblings. Cancer Cell, 311-313, 1 May 2002
(http://www.cell.com/cancer-cell/retrieve/pii/S1535610802000648)
b.Mitchell A. Apoptosis: The p53 mafia. Nature Reviews Cancer 2, 326 (May 2002)
http://www.nature.com/nrc/journal/v2/n5/full/nrc804.html
c. Faculty of 1000 – rated 6 (William Kaelin, M.D., Professor, Harvard Medical School, Dana Farber Cancer Institute)